Long-Term Follow-Up of Longevity and Diffusion Pattern of Hyaluronic Acid in Nasolabial Fold Correction through High-Frequency Ultrasound.
Adult
Aged
Allantoin
/ therapeutic use
Cosmetic Techniques
Dermal Fillers
/ administration & dosage
Drug Combinations
Esthetics
Female
Follow-Up Studies
Hexachlorophene
/ therapeutic use
Humans
Hyaluronic Acid
/ analogs & derivatives
Injections, Intradermal
Male
Middle Aged
Nasolabial Fold
/ physiopathology
Risk Assessment
Single-Blind Method
Skin Aging
/ drug effects
Squalene
/ therapeutic use
Taiwan
Time Factors
Treatment Outcome
Ultrasonic Therapy
/ methods
Journal
Plastic and reconstructive surgery
ISSN: 1529-4242
Titre abrégé: Plast Reconstr Surg
Pays: United States
ID NLM: 1306050
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
entrez:
27
7
2019
pubmed:
28
7
2019
medline:
16
11
2019
Statut:
ppublish
Résumé
Injectable hyaluronic acid fillers have been widely applied in the clinical treatment of facial wrinkles. However, further information and clinical evidence concerning dermal changes and hyaluronic acid filler longevity after injection and diffusion pattern are limited. The authors evaluated the longevity and diffusion pattern of two hyaluronic acid fillers generated by different cross-linking technologies used in the treatment of nasolabial folds using high-frequency ultrasound. Forty-one subjects were treated with Restylane 2 and the remaining 41 were treated with Dermalax DEEP. Wrinkle severity rating scale score and high-frequency ultrasound evaluation of nasolabial folds were performed before and after the injection of hyaluronic acid filler. The ultrasound images were acquired and analyzed to determine dermal thickness and the shape and distribution of hyaluronic acid filler. At 2 and 24 weeks from baseline, increased dermal thickness induced by hyaluronic acid filler treatment was not significantly different between groups. At 48 weeks after injection, increased dermal thicknesses of the Restylane 2 group (0.14 ± 0.12 mm) were much lower than those of the Dermalax DEEP group (0.20 ± 0.13 mm). Ultrasound examination revealed that hyaluronic acid materials form well-demarcated and hypoechogenic areas. Restylane 2 tended to form a more diffuse pattern, with multiple smaller bubbles, whereas Dermalax DEEP developed into a more localized configuration, with larger clumps. This study is the first long-term assessment of nasolabial fold correction that reveals the performance of different hyaluronic acid materials in vivo and validates high-frequency ultrasound as a simple and rapid modality. Hyaluronic acid fillers generated by different cross-linking technologies display differential diffusion patterns in skin tissues. Therapeutic, II.
Sections du résumé
BACKGROUND
Injectable hyaluronic acid fillers have been widely applied in the clinical treatment of facial wrinkles. However, further information and clinical evidence concerning dermal changes and hyaluronic acid filler longevity after injection and diffusion pattern are limited.
METHODS
The authors evaluated the longevity and diffusion pattern of two hyaluronic acid fillers generated by different cross-linking technologies used in the treatment of nasolabial folds using high-frequency ultrasound. Forty-one subjects were treated with Restylane 2 and the remaining 41 were treated with Dermalax DEEP. Wrinkle severity rating scale score and high-frequency ultrasound evaluation of nasolabial folds were performed before and after the injection of hyaluronic acid filler. The ultrasound images were acquired and analyzed to determine dermal thickness and the shape and distribution of hyaluronic acid filler.
RESULTS
At 2 and 24 weeks from baseline, increased dermal thickness induced by hyaluronic acid filler treatment was not significantly different between groups. At 48 weeks after injection, increased dermal thicknesses of the Restylane 2 group (0.14 ± 0.12 mm) were much lower than those of the Dermalax DEEP group (0.20 ± 0.13 mm). Ultrasound examination revealed that hyaluronic acid materials form well-demarcated and hypoechogenic areas. Restylane 2 tended to form a more diffuse pattern, with multiple smaller bubbles, whereas Dermalax DEEP developed into a more localized configuration, with larger clumps.
CONCLUSIONS
This study is the first long-term assessment of nasolabial fold correction that reveals the performance of different hyaluronic acid materials in vivo and validates high-frequency ultrasound as a simple and rapid modality. Hyaluronic acid fillers generated by different cross-linking technologies display differential diffusion patterns in skin tissues.
CLINICAL QUESTION/LEVEL OF EVIDENCE
Therapeutic, II.
Identifiants
pubmed: 31348336
doi: 10.1097/PRS.0000000000005848
pii: 00006534-201908000-00012
pmc: PMC6661240
doi:
Substances chimiques
Dermal Fillers
0
Drug Combinations
0
allantoin, hexachlorophene, squalene drug combination
0
Allantoin
344S277G0Z
Squalene
7QWM220FJH
Hyaluronic Acid
9004-61-9
Hexachlorophene
IWW5FV6NK2
Restylane
S270N0TRQY
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
189e-196eRéférences
Plast Reconstr Surg. 2015 Nov;136(5 Suppl):188S-195S
pubmed: 26441098
Aesthet Surg J. 2014 May 1;34(4):510-5
pubmed: 24667463
Plast Reconstr Surg. 2018 Jul;142(1):112-121
pubmed: 29952893
Skin Res Technol. 2008 Aug;14(3):320-3
pubmed: 19159378
Dermatol Surg. 2012 Jul;38(7 Pt 2):1143-50
pubmed: 22759250
Aesthetic Plast Surg. 2013 Jun;37(3):587-91
pubmed: 23620006
Arch Facial Plast Surg. 2009 Jul-Aug;11(4):240-5
pubmed: 19620529
Facial Plast Surg Clin North Am. 2007 Feb;15(1):63-76, vii
pubmed: 17317557
Dermatol Surg. 2010 Nov;36 Suppl 3:1843-51
pubmed: 20969661
Skin Res Technol. 2007 Nov;13(4):385-9
pubmed: 17908189
Aesthetic Plast Surg. 2015 Feb;39(1):129-33
pubmed: 25539986
J Appl Biomater Biomech. 2011 May-Aug;9(2):127-36
pubmed: 22065390
Aesthet Surg J. 2012 Feb;32(2):207-19
pubmed: 22328690
J Dermatol Sci. 2013 Mar;69(3):187-94
pubmed: 23340440
Dermatol Ther (Heidelb). 2013 Jan 08;3(1):83-93
pubmed: 23888258
J Drugs Dermatol. 2013 Sep;12(9):990-4
pubmed: 24002145
J Dermatol Sci. 2010 Mar;57(3):214-6
pubmed: 20137898